Ultragenyx Pharmaceutical heads into the back half of June with a sharp disconnect between its 9% weekly rally and an options market suddenly pricing in the most defensive posture it has struck in nearly a year.
The clearest signal this week is in options. The put/call ratio jumped to 0.997 on Tuesday — almost exactly even money between puts and calls — which sounds unremarkable until you see the context: the 20-day average is just 0.70, and the current reading sits 3.6 standard deviations above that mean. That z-score is close to the 52-week high of 1.10. In other words, options traders are buying downside protection at a rate that is nearly unprecedented for this stock, even as the share price closed Monday at $24.85 — up sharply from where it started the week. The divergence between price action and options positioning is the most interesting tension in RARE right now.
Short interest reinforces the caution. Bears have been steadily rebuilding positions through June, with short interest climbing roughly 6.4% on the week and 4.2% over the past month, now representing 15.3% of the free float — a genuinely elevated level for any biotech. That is around 14.7 million shares short, and the rebuild has been consistent: positions bottomed near 13.7 million in early May and have ground higher almost every week since. Critically, the borrow market is not yet signalling stress. Availability is deeply loose at over 1,300%, meaning roughly 91.7 million shares remain available to borrow — far more than the 14.7 million currently short. Cost to borrow has climbed 58% over the past month in percentage terms but remains low in absolute terms at 0.61%. This is a situation where bears are growing bolder, but the lending market is offering them no friction whatsoever.
The Street is divided, and the analyst picture has been messy since early spring. Cantor Fitzgerald raised its target to $96 in May while maintaining Overweight, and Morgan Stanley had lifted to $67 in April — both bullish moves. But Goldman Sachs downgraded to Neutral in late March and cut its target to $25, essentially in line with where the stock is trading today. Guggenheim and Barclays trimmed targets while holding constructive ratings, and Wedbush sat out both sides at Neutral with a $26 target. The mean across the analyst panel sits near $52 — roughly double the current price — but that figure is heavily skewed by the outlier bulls; the bear camp, anchored by Goldman, sees the stock as fairly valued at current levels. The bull case rests on Crysvita revenue momentum and a path to GAAP profitability by 2027. The bear case is that FY26 revenue guidance of around $742 million already came in below prior consensus expectations, the company posted a net loss of $5.83 per share in FY25, and the cost-reduction programme signals limited near-term reinvestment capacity. Forward EPS revisions rank in the 96th percentile — a striking score — but that reflects improvement from a deeply negative base, not a profitable business.
Institutional ownership offers one modest counterweight to the cautious tone. BlackRock added nearly 668,000 shares in the most recent reporting period, lifting its stake to 7.4% of shares outstanding. State Street also added 718,000 shares. Those are meaningful incremental buys from passive-and-active giants, though they are likely index-flow-driven rather than conviction calls. Insider activity over the past 90 days has been uniformly one-directional: the CFO sold three separate tranches between March and June, the Chief Legal Officer sold twice, and both a director and an independent board member sold last week. Net insider activity over 90 days amounts to a sell of roughly $575,000 in value — modest in dollar terms but consistent in direction.
With the next earnings event scheduled for August 3, the sharpest signal to monitor is whether that put/call ratio normalises or extends as the summer progresses. A PCR that holds above 0.90 into July would suggest options traders are actively hedging the earnings date rather than reacting to short-term noise — and that, combined with a short interest base already at 15% of float, would create a charged setup heading into the Q2 print.
See the live data behind this article on ORTEX.
Open RARE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
